Bayer, Hologic unite to improve availability of contrast-enhanced mammography

Bayer and diagnostic imaging company Hologic are coordinating to improve the supply and availability of contrast-enhanced mammography (CEM). As part of the agreement, Bayer’s contrast delivery system will be combined with Hologic’s mammography scanners.

The companies said the move will streamline imaging workflows and make the purchasing process simpler, while improving the availability of CEM for patients. Setup and ongoing maintenance services for the CEM system is part of the package deal.

The resulting Medrad Stellant Flex CT Injection System and Certegra workstation is the first and only CT injection system cleared by the U.S. Food and Drug Administration (FDA) for use with additional contrast-enhanced mammography application.

“We are thrilled to work with Hologic to increase access to this emerging breast imaging modality,” Sven Schmidt, head of the Americas region for Bayer, said in a statement. “Together we will deliver an innovative and coordinated solution for both patients and healthcare professionals alike.”

The partnership began last year with an agreement to work together for the detection of breast cancer.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Ultrafast MCE could go on to become a go-to treatment option for obstructive coronary artery disease, according to the authors of a new first-in-human clinical study.

Elucid's PlaqueIQ was trained to turn CCTA images into interactive 3D reports that help physicians visualize the presence of atherosclerosis.

Trimed Popup
Trimed Popup